Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 5/20 | 0.41 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | NNMT | P40261 | 6/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947419 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL18589317 | 1.00 | UBA6 (0.41) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL1795550 | 0.90 | UBA6 (0.40) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL23892218 | 0.88 | PRMT5 (0.47) | UBA6NAE1PRMT5WDR77NNMT | |
| SCHEMBL16943624 | 0.86 | UBA6 (0.41) | UBA6PRMT5WDR77NNMT | |
| SCHEMBL191943 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL10186224 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL25048671 | 0.85 | UBA6 (0.42) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL19563037 | 0.85 | ADK (0.48) | PRMT5WDR77 | |
| SCHEMBL16769947 | 0.83 | PRMT5 (0.44) | UBA6PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368165-A1 | SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3091020-B1 | HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | MILLENNIUM PHARM INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540727-B1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARM INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10016427-B2 | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate | Millennium Pharmacetuicals, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2879681-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 | Millennium Pharmaceuticals, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933225-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2014022744-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| EP-2546256-A2 | Process for the synthesis of intermediates compounds useful for the preparation of E1 activity activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2540726-A1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540727-A1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20110021544-A1 | HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016427-B2 | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate | SULT1E1, SULT1A1, STS | UBA6 3883/4885NAE1 39/4885CA2 176/4885 |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | UBA6 1242/4885NAE1 52/4885CA2 2803/4885 |
| US-20240368165-A1 | SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | SULT1E1, SRM, SULT1A1 | UBA6 4743/4885NAE1 4365/4885CA2 341/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | UBA6 927/4885NAE1 50/4885CA2 3185/4885 |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | UBA6 927/4885NAE1 50/4885CA2 3185/4885 |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | UBA6, UBE2V1, UBA1 | UBA6 1/4885NAE1 344/4885CA2 4672/4885 |
| US-20110021544-A1 | HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE | SULT1E1, SULT1A1, SULT2A1 | UBA6 2934/4885NAE1 37/4885CA2 161/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | UBA6 984/4885NAE1 53/4885CA2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.